Compare IHG & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IHG | EXAS |
|---|---|---|
| Founded | 1777 | 1995 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.5B | 19.7B |
| IPO Year | 2000 | 2000 |
| Metric | IHG | EXAS |
|---|---|---|
| Price | $140.55 | $103.35 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 18 |
| Target Price | N/A | ★ $85.64 |
| AVG Volume (30 Days) | 236.1K | ★ 2.1M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 1.19% | N/A |
| EPS Growth | N/A | ★ 80.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,144,000.00 |
| Revenue This Year | $9.51 | $15.18 |
| Revenue Next Year | $5.62 | $12.46 |
| P/E Ratio | $29.84 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $94.78 | $38.88 |
| 52 Week High | $150.89 | $103.87 |
| Indicator | IHG | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 46.62 | 65.17 |
| Support Level | $133.08 | $101.12 |
| Resistance Level | $144.96 | $103.87 |
| Average True Range (ATR) | 3.30 | 0.33 |
| MACD | -0.60 | -0.13 |
| Stochastic Oscillator | 5.23 | 66.15 |
InterContinental Hotels Group operates 987,000 rooms across 20 brands addressing the midscale through luxury segments, as of Dec. 31, 2024. Holiday Inn and Holiday Inn Express constitute the largest brand, while Hotel Indigo, Even, Hualuxe, Kimpton, and Voco are newer lifestyle brands experiencing strong demand. The company launched a midscale brand, Avid, in 2017 and closed on a 51% stake in Regent Hotels in 2018. It acquired Six Senses in 2019 and launched another midscale brand, Garner, in 2023. Managed and franchised represent 99% of total rooms. As of Dec. 31, 2024, the Americas represented 53% of total rooms, with Greater China accounting for 20% and Europe, Asia, the Middle East, and Africa making up 27%.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.